Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Sectoral/ Thematic median (250 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 04 Oct 2023 – 20 Aug 2026, limited by HDFC Pharma and Healthcare Fund. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | HDFC Pharma and Healthcare Fund | Nifty 500 |
|---|---|---|
| 04 Oct 2023 | ₹100.00 | ₹100.00 |
| 31 Dec 2023 | ₹113.96 | ₹113.47 |
| 27 Mar 2024 | ₹122.53 | ₹117.31 |
| 23 Jun 2024 | ₹132.05 | ₹129.86 |
| 18 Sep 2024 | ₹162.66 | ₹139.57 |
| 15 Dec 2024 | ₹166.45 | ₹136.42 |
| 13 Mar 2025 | ₹154.60 | ₹117.83 |
| 08 Jun 2025 | ₹167.62 | ₹135.29 |
| 04 Sep 2025 | ₹177.13 | ₹133.27 |
| 30 Nov 2025 | ₹180.65 | ₹139.77 |
| 26 Feb 2026 | ₹185.01 | ₹136.94 |
| 24 May 2026 | ₹199.78 | ₹132.29 |
| 20 Aug 2026 | ₹221.77 | ₹137.32 |
| Metric | HDFC · Direct · IDCW NAV ₹22.10 Very High risk ★★★★★ 1Y | Category median Sectoral/ Thematic · 250 funds |
|---|---|---|
| +24.61% | +5.11% | |
| — | +13.02% | |
| — | +11.14% | |
| — | +12.26% | |
| +31.89% | +11.82% | |
| +27.23% | — | |
| — | +14.62% | |
| — | +12.95% | |
| — | +13.24% | |
| Risk | ||
| 14.08% | 15.88% | |
| 1.29 | 0.35 | |
| 1.85 | 0.47 | |
| -14.91% | -25.18% | |
| Nifty 500 | — | |
| +18.95% | +1.40% | |
| 0.71 | 0.98 | |
| 126.6% | 101.5% | |
| 32.4% | 97.0% | |
| 1.09% | 1.14% | |
| ₹2,282Cr | ₹1,162Cr | |
| 1.00% | — | |
| None | — | |
| ₹100 | — | |
| ₹129 | — | |
| 42% | 45% | |
| Dhruv Muchhal | — | |
| 04 Oct 2023 | — | |
| 35 | — | |
| 54.1% | — | |
| 2.8% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.